Annual Total Long Term Liabilities
$98.87 M
-$11.49 M-10.41%
31 December 2023
Summary:
Poseida Therapeutics annual total long term liabilities is currently $98.87 million, with the most recent change of -$11.49 million (-10.41%) on 31 December 2023. During the last 3 years, it has risen by +$19.38 million (+24.37%). PSTX annual total long term liabilities is now -64.00% below its all-time high of $274.65 million, reached on 31 December 2019.PSTX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$128.10 M
-$7.34 M-5.42%
30 September 2024
Summary:
Poseida Therapeutics quarterly total long term liabilities is currently $128.10 million, with the most recent change of -$7.34 million (-5.42%) on 30 September 2024. Over the past year, it has increased by +$26.48 million (+26.06%). PSTX quarterly long term liabilities is now -68.20% below its all-time high of $402.76 million, reached on 30 June 2020.PSTX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTX Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -10.4% | +26.1% |
| 3 y3 years | +24.4% | +60.2% |
| 5 y5 years | -9.1% | - |
PSTX Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -10.4% | +41.7% | -5.4% | +83.6% |
| 5 y | 5 years | -64.0% | +41.7% | -68.2% | +84.6% |
| alltime | all time | -64.0% | +91.0% | -68.2% | +84.6% |
Poseida Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $128.10 M(-5.4%) |
| June 2024 | - | $135.44 M(+45.3%) |
| Mar 2024 | - | $93.22 M(-5.7%) |
| Dec 2023 | $98.87 M(-10.4%) | $98.87 M(-2.7%) |
| Sept 2023 | - | $101.62 M(+5.8%) |
| June 2023 | - | $96.03 M(-10.6%) |
| Mar 2023 | - | $107.37 M(-2.7%) |
| Dec 2022 | $110.36 M(+58.2%) | $110.36 M(-4.2%) |
| Sept 2022 | - | $115.20 M(+15.7%) |
| June 2022 | - | $99.56 M(-1.0%) |
| Mar 2022 | - | $100.53 M(+44.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $69.76 M(-12.2%) | $69.76 M(-12.8%) |
| Sept 2021 | - | $79.98 M(-0.7%) |
| June 2021 | - | $80.54 M(+3.2%) |
| Mar 2021 | - | $78.06 M(-1.8%) |
| Dec 2020 | $79.49 M(-71.1%) | $79.49 M(-0.1%) |
| Sept 2020 | - | $79.56 M(-80.2%) |
| June 2020 | - | $402.76 M(+480.3%) |
| Mar 2020 | - | $69.41 M(-74.7%) |
| Dec 2019 | $274.65 M(+152.4%) | $274.65 M |
| Dec 2018 | $108.81 M(+110.3%) | - |
| Dec 2017 | $51.75 M | - |
FAQ
- What is Poseida Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Poseida Therapeutics?
- What is Poseida Therapeutics annual total long term liabilities year-on-year change?
- What is Poseida Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly long term liabilities year-on-year change?
What is Poseida Therapeutics annual total long term liabilities?
The current annual total long term liabilities of PSTX is $98.87 M
What is the all time high annual total long term liabilities for Poseida Therapeutics?
Poseida Therapeutics all-time high annual total long term liabilities is $274.65 M
What is Poseida Therapeutics annual total long term liabilities year-on-year change?
Over the past year, PSTX annual total long term liabilities has changed by -$11.49 M (-10.41%)
What is Poseida Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of PSTX is $128.10 M
What is the all time high quarterly long term liabilities for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly total long term liabilities is $402.76 M
What is Poseida Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, PSTX quarterly total long term liabilities has changed by +$26.48 M (+26.06%)